Livforsakringsbolaget Skandia’s Bio-Rad Laboratories Class A BIO Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-271	Closed	-$66K	–	533
2025 Q1	$66K	Hold	271	–	–	﹤0.01%	530
2024 Q4	$89K	Hold	271	–	–	﹤0.01%	508
2024 Q3	$90.6K	Buy	271 +200	+282%	+$63.5K	﹤0.01%	531
2024 Q2	$19.4K	Hold	71	–	–	﹤0.01%	495
2024 Q1	$24.5K	Hold	71	–	–	﹤0.01%	481
2023 Q4	$22.9K	Buy	+71	New	+$22.3K	﹤0.01%	481
2022 Q3	–	Sell	-200	Closed	-$99K	–	587
2022 Q2	$99K	Sell	200 -200	-50%	-$104K	0.01%	458
2022 Q1	$225K	Hold	400	–	–	0.02%	441
2021 Q4	$302K	Hold	400	–	–	0.02%	394
2021 Q3	$298K	Sell	400 -100	-20%	-$74.9K	0.02%	440
2021 Q2	$322K	Buy	500 +300	+150%	+$183K	0.02%	463
2021 Q1	$114K	Hold	200	–	–	0.01%	582
2020 Q4	$117K	Hold	200	–	–	0.01%	559
2020 Q3	$103K	Hold	200	–	–	0.01%	533
2020 Q2	$90K	Hold	200	–	–	0.01%	555
2020 Q1	$70K	Buy	+200	New	+$73.5K	0.01%	545

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Livforsakringsbolaget Skandia's BIO Position: Q2 2025 in Review

Livforsakringsbolaget Skandia sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 271 shares — an estimated $66K sold.

Livforsakringsbolaget Skandia first reported a position in BIO in Q1 2020 and held it in 16 quarters. The position peaked at $322K in Q2 2021. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Livforsakringsbolaget Skandia reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 271 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $66K.
Livforsakringsbolaget Skandia first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 16 quarters.
Livforsakringsbolaget Skandia's Bio-Rad Laboratories Class A position peaked at $322K in Q2 2021.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Livforsakringsbolaget Skandia's 13F filing for Q2 2025, filed 9 Jul 2025.